Growth Drivers
What could change its growth trajectory, and what would confirm it?
Jiuzhou Pharmaceutical's growth driver is its early-stage CDMO order base: by June 2022 it had received 700 CDMO contracts, 662 of them for Phase 1 and Phase 2 clinical trials, and the first half of 2022 brought a 58% revenue surge to 2.95 billion Chinese yuan.
Jiuzhou Pharmaceutical's annual revenue was 5.51 billion in 2025, up 6.74%. Over the twelve months to September 30, 2026, revenue was 5.28 billion, down 1.33% year over year.
Risk Factors
Which risks could break the thesis, and what would warn of them?
Customer concentration is the risk most able to break Jiuzhou Pharmaceutical's thesis, because a handful of buyers carry its revenue: its five largest customers accounted for 65.32% of annual sales, and Novartis accounted for 54.50% of Jiuzhou Pharmaceutical's annual sales.
Jiuzhou Pharmaceutical's revenue for the twelve months to September 30, 2026, was 5.28B, down 1.33% year over year. Its 2025 annual revenue was 5.51B, up 6.74%.
Product Overview
What does the product do for its buyer, and how is it delivered?
Jiuzhou Pharmaceutical provides one-stop CDMO services spanning preclinical CMC through Phase I/II/III trials, new drug applications, and global marketing, with drug-product work covering dosage form design, formulation process R&D, quality studies, stability testing, and commercial production. At the end of 2023, it established an Animal Health unit to serve animal-health companies.
Jiuzhou Pharmaceutical's manufacturing network includes more than 50 production lines across specialized and multipurpose workshops and pilot plants, covering kilogram- to tonne-scale production. The company operates high-potency production facilities with two OEB 5 and six OEB 4 lines, and its services span the entire industry chain from intermediates to APIs and DPs.